Florian Wanke

Florian Wanke

Auto-generated profile, based on publicly available information

Florian Wanke

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SGSimon Gutbier
Simon Gutbier
FWFlorian Wanke
Florian Wanke
NDNadine Dahm
Nadine Dahm
ARAnna Rümmelin
Anna Rümmelin
SZSilke Zimmermann
Silke Zimmermann
CPChristoph Patsch
Christoph Patsch
Tissue-resident macrophages are key players in inflammatory processes, and their activation and functionality are crucial in health and disease. Numerous diseases are associated with alterations in homeostasis or dysregulation of the innate immune system, including allergic reactions, autoimmune diseases, and cancer. Macrophages are a prime target for drug discovery due to their major regulatory role in health and disease. Currently, the main sources of macrophages used for therapeutic compound screening are primary cells isolated from blood or tissue or immortalized or neoplastic cell lines (e.g., THP-1). Here, we describe an improved method to employ induced pluripotent stem cells (iPSCs) for the high-yield, large-scale production of cells resembling tissue-resident macrophages. For this, iPSC-derived macrophage-like cells are thoroughly characterized to confirm their cell identity and thus their suitability for drug screening purposes. These iPSC-derived macrophages show strong cellular identity with primary macrophages and recapitulate key functional characteristics, including cytokine release, phagocytosis, and chemotaxis. Furthermore, we demonstrate that genetic modifications can be readily introduced at the macrophage-like progenitor stage in order to interrogate drug target-relevant pathways. In summary, this novel method overcomes previous shortcomings with primary and leukemic cells and facilitates large-scale production of genetically modified iPSC-derived macrophages for drug screening applications.

25 May 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FWFlorian Wanke
Florian Wanke
SGSimon Gutbier
Simon Gutbier
ARAnna Rümmelin
Anna Rümmelin
MSMalte Steinberg
Malte Steinberg
LHLindsey D. Hughes
Lindsey D. Hughes
BGBarbara Geering
Barbara Geering
Removal of apoptotic cells by phagocytes (also called efferocytosis) is a crucial process for tissue homeostasis. Professional phagocytes express a plethora of surface receptors enabling them to sense and engulf apoptotic cells, thus avoiding persistence of dead cells and cellular debris and their consequent effects. Dysregulation of efferocytosis is thought to lead to secondary necrosis and associated inflammation and immune activation. Efferocytosis in primarily murine macrophages and dendritic cells has been shown to require TAM RTKs, with MERTK and AXL being critical for clearance of apoptotic cells. The functional role of human orthologs, especially the exact contribution of each individual receptor is less well studied. Here we show that human macrophages differentiated in vitro from iPSC-derived precursor cells express both AXL and MERTK and engulf apoptotic cells. TAM RTK agonism by the natural ligand growth-arrest specific 6 (GAS6) significantly enhanced such efferocytosis. Using a newly-developed mouse model of kinase-dead MERTK, we demonstrate that MERTK kinase activity is essential for efferocytosis in peritoneal macrophages in vivo. Moreover, human iPSC-derived macrophages treated in vitro with blocking antibodies or small molecule inhibitors recapitulated this observation. Hence, our results highlight a conserved MERTK function between mice and humans, and the critical role of its kinase activity in homeostatic efferocytosis.

9 May 2018 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
LBL. Barington
L. Barington
FWF. Wanke
F. Wanke
KAK. Niss Arfelt
K. Niss Arfelt
PHPeter Johannes Holst
Peter Johannes Holst
FKFlorian Kurschus
Florian Kurschus
MRmette rosenkilde
mette rosenkilde

10 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
SLSimona Lange
Simona Lange
MEMartin Ebeling
Martin Ebeling
ALAthéna Loye
Athéna Loye
FWFlorian Wanke
Florian Wanke
JSJuliane Siebourg-Polster
Juliane Siebourg-Polster
JHJan Hoeber
Jan Hoeber
Oligodendrocytes, the myelinating cells of the central nervous system (CNS), are essential for the formation of myelin sheaths and pivotal for maintaining axonal integrity and conduction. Disruption of these cells and the myelin sheaths they produce is a hallmark of demyelinating conditions like multiple sclerosis or those resulting from certain drug side effects, leading to profound neurological impairments. In this study, we created a human brain organoid comprising neurons, astrocytes, and myelinating oligodendrocytes. By integrating induced pluripotent stem cell–derived microglia, we endowed these myelinated human brain organoids (MHBOs) with immune characteristics. MHBOs with microglia (MHBOs +MG) enabled the investigation of demyelination and remyelination—a process in which myelin sheaths are regenerated—in a human context. After toxin-induced demyelination, we observed a reduction in myelin followed by subsequent self-driven remyelination. Proteomic and transcriptomic analyses provided a molecular signature of demyelination and myelin recovery indicating a central role for microglia in the remyelination process. Furthermore, the application of the pro-remyelinating compounds clemastine, XAV939, and BQ3020 further enhanced remyelination in MHBOs +MG but was ineffective in the absence of microglia. Cross-validation of our findings in mouse cerebellar slice cultures confirmed that the pro-remyelinating compounds were effective ex vivo, suggesting the translational potential of our MHBOs +MG model.

29 June 2018 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
FWFlorian Wanke
Florian Wanke
YTYilang Tang
Yilang Tang
KGKonrad Gronke
Konrad Gronke
SKSabrina Klebow
Sabrina Klebow
SMSonja Moos
Sonja Moos
AWAri Waisman
Ari Waisman

2 February 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SMSonja Moos
Sonja Moos
TRTommy Regen
Tommy Regen
FWFlorian Wanke
Florian Wanke
YTYizhu Tian
Yizhu Tian
LALucas T. Arendholz
Lucas T. Arendholz
FKFlorian Kurschus
Florian Kurschus